MEG3 and heart failure: Atrial natriuretic peptide (ANP) is a biomarker used in heart failure that is closely related to the severity of ventricular remodelling.17, 18 Our preliminary analysis by UCG indicated improved cardiac function following lncRNA MEG3 siRNA treatment.